New work programme for NICE announced

As part of its 13th work programme, the National Institute for Clinical Excellence (NICE) is being asked to develop technology appraisals on new treatments for conditions including breast cancer and obesity. This includes Lapatinib for advanced or metastatic breast cancer: to appraise the clinical and cost effectiveness of lapatinib plus capecitabine within its licensed indications for advanced, metastatic or recurrent breast cancer. Rimonabant for the treatment of obese and overweight patients: to appraise the clinical and cost effectiveness of rimonabant in its licensed indications as an adjunct to diet and exercise for the treatment of obese and overweight patients. Further details can be found on the website, link below.

Link to press release